Contrast-enhanced Multispectral Optoacoustic Tomography for Non-invasive Assessment of Diabetic Gastroparesis (TRANSPARENT)

nclusion criteria Group 1 Written informed consent T1DM diagnosis Duration of disease at least 5, preferably 10 years with diagnosed neuropathy Group 2 Written informed consent T1DM diagnosis Duration of disease at least 5, preferably 10 years without diagnosed neuropathy Group 3 Written informed consent from parent or guardian T1DM diagnosis Duration of disease at least 5, preferably 10 years with inadequate medication control (HbA1c value > 8.5 mmol/l) Group 4 Written informed consent of parent or guardian T1DM diagnosis Duration of disease at least 5, preferably 10 years with good medication control (HbA1c value < 7.5 mmol/l) Exclusion criteria Generality: Pregnancy Breastfeeding mothers Tattoo in the area of the examination Subcutaneous fat tissue over 3 cm Known hypersensitivity to ICG, sodium iodide or iodine Hyperthyroidism, focal or diffuse thyroid autonomy Timely close treatment to check thyroid function with ingestion of radioactive iodine (within two weeks before or after the study) Impaired renal function Taking the following medications: Beta blockers, anticonvulsants, cyclopropane, bisulfite compounds, haloperidol, heroin, meperidine, metamizole, methadone, morphine, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, probenecid, rifamycin, any injection containing sodium bisulfite